Abstract
Characteristic symptoms of schizophrenia and bipolar disorders have been described and classified about a century ago. Each of these disorders may cause considerable impairment reflecting substantial alterations in cognition, perception, and mood. Though both disease concepts are well established, psychopharmacological treatment strategies, involving first- and second-generation antipsychotics, benzodiazepines and mood stabilizing drugs, often fail to keep their purported alleviating effects on respective characteristic symptom spectra, producing unsatisfactory patient responses. While drug profiles may differ concerning the underlying mechanism of action, the breadth of treatment options remains limited. Besides developing new drugs with different mechanisms of action, side-effect profile and efficacy, it has to be emphasized that repurposed drugs might serve as alternative or adjuvant treatment options for patients, who continue to poorly respond to standard treatment algorithms. Here, we review the current evidence of selected drugs whose repurposed use might expand the range of treatment options for schizophrenia and bipolar disorders.
Keywords: Medical need, antipsychotics, treatment resistance, adherence, oxytocin, omega-3 fatty acids.
Current Topics in Medicinal Chemistry
Title:Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Volume: 13 Issue: 18
Author(s): J. M. Bumb, F. Enning and F. M. Leweke
Affiliation:
Keywords: Medical need, antipsychotics, treatment resistance, adherence, oxytocin, omega-3 fatty acids.
Abstract: Characteristic symptoms of schizophrenia and bipolar disorders have been described and classified about a century ago. Each of these disorders may cause considerable impairment reflecting substantial alterations in cognition, perception, and mood. Though both disease concepts are well established, psychopharmacological treatment strategies, involving first- and second-generation antipsychotics, benzodiazepines and mood stabilizing drugs, often fail to keep their purported alleviating effects on respective characteristic symptom spectra, producing unsatisfactory patient responses. While drug profiles may differ concerning the underlying mechanism of action, the breadth of treatment options remains limited. Besides developing new drugs with different mechanisms of action, side-effect profile and efficacy, it has to be emphasized that repurposed drugs might serve as alternative or adjuvant treatment options for patients, who continue to poorly respond to standard treatment algorithms. Here, we review the current evidence of selected drugs whose repurposed use might expand the range of treatment options for schizophrenia and bipolar disorders.
Export Options
About this article
Cite this article as:
Bumb M. J., Enning F. and Leweke M. F., Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders, Current Topics in Medicinal Chemistry 2013; 13 (18) . https://dx.doi.org/10.2174/15680266113136660165
DOI https://dx.doi.org/10.2174/15680266113136660165 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Synthesis, Biological Evaluation and in silico Studies of Novel 5α-aza-Bhomo-3,5-secosteroids as Potential 5-reductase Inhibitors
Letters in Drug Design & Discovery Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers
Current Drug Targets Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine An Overview on Applications of Gold Nanoparticle for Early Diagnosis and Targeted Drug Delivery to Prostate Cancer
Recent Patents on Nanotechnology Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Current Medicinal Chemistry Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Editorial [Hot Topic: Environmental Impacts on Enzymes Involved in Drug and Steroid Metabolism Guest Editor: R.H. Waring ]
Current Drug Metabolism Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery The Effects of Kisspeptin in Human Reproductive Function – Therapeutic Implications
Current Drug Targets